Pitch Deck: Grant Pickering (MBA’97) Takes His Shot
Bacterial infectious diseases remain a leading global cause of death and a significant driver of antimicrobial resistance. Vaxcyte is a clinical-stage vaccine innovation company focused on creating high-fidelity vaccines that prevent or treat some of the most common and deadly infectious diseases.
We are re-engineering how highly complex vaccines are made using our proprietary cell-free protein synthesis platform. Our lead candidate, VAX-24, received FDA Breakthrough Therapy Designation for the treatment of invasive pneumococcal disease in adults. We believe VAX-24 has the potential to deliver broader coverage and better immune responses than available vaccines in both adults and children.
With a global mission to protect humankind from the consequences of bacterial diseases, our pre-clinical pipeline also includes a vaccine for Group A Strep, and a therapeutic vaccine for periodontitis. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.
— Grant Pickering (MBA’97), founder and CEO of Vaxcyte
This story was originally featured in the Georgetown Business Spring 2023 Magazine.